Rua Bioscience inks NZ$10m UK medical cannabis deal

Rua Bioscience’s UK Breakthrough Deal

Rua Bioscience Limited (NZX:RUA) has landed its most significant export agreement yet, partnering with one of the UK’s largest medicinal cannabis clinic and distribution businesses. The deal, expected to generate over NZ$10 million in revenue across two years, marks a major leap for the New Zealand-based company into one of the world’s fastest-growing medical cannabis markets.

By supplying New Zealand-grown medical cannabis flower, Rua taps into the UK’s rapidly expanding sector, where dispensed volumes more than doubled year-on-year, reaching 30 tonnes in 2025. This volume surge corresponds with a market value estimated at £226 million, reflecting 103% growth from the previous year.

Strategic Access to UK Networks

The agreement grants Rua immediate entry into an established network of clinics, pharmacies, and prescribers; connections that would otherwise take years to cultivate. This strategic shortcut positions Rua not just as a supplier but as a credible player in a market where nearly 100,000 patients currently access medical cannabis, against a potential eligible population of up to three million.

Rua’s CEO Paul Naske emphasised the importance of this milestone, highlighting the company’s focus on leveraging New Zealand’s unique cannabis genetics in high-value international markets. The partnership aligns Rua alongside global leaders in medical cannabis, enhancing its brand and commercial prospects internationally.

Expanding Global Footprint Amid Market Momentum

This UK deal complements Rua’s growing international presence, which already spans Germany, Australia, Canada, Czech Republic, and New Zealand. The company pursues a capital-light strategy centred on differentiated genetics, aiming to carve out niche positions in multiple markets rather than heavy domestic production.

While the UK partner remains unnamed due to ongoing communications, the agreement’s scale and strategic nature underscore Rua’s ambition to capitalise on the import-dependent UK market, which remains hungry for quality-assured international producers.

As the UK’s medical cannabis sector continues its rapid growth trajectory, Rua’s timely entry and established partnerships could set the stage for meaningful near-term returns and longer-term brand development.